-
Semaglutide can be prescribed as an adjunct to a low calorie diet and increased physical activity for chronic weight management in overweight and obese adults.
-
In addition to identifying several patient risk factors for contamination of blood culture specimens, the authors also highlighted various adverse clinical and financial adverse effects.
-
Cholinesterase inhibitors are one of the few drug classes approved by the FDA to treat patients with Alzheimer’s disease. This study shows a long-term benefit in slowing the decline of cognition, but it is unclear if there is any benefit in quality of life.
-
Disparate public health messaging from political officials, news media, and online outlets has occurred throughout the COVID-19 pandemic in the United States. Some have wanted to ascribe lower rates of compliance with public health guidance to political affiliation.
-
Researchers found many survivors of COVID-19 exhibited significant loss of health six months after their acute illness, with greater risk associated with severity of the acute infection.
-
An analysis of the utility of implanted loop recorders to detect subclinical atrial fibrillation in high-risk individuals showed that among common arrhythmia-compatible symptoms, only palpitation was predictive of discovering episodes of atrial fibrillation.
-
How would one interpret the ECG in the figure, obtained in the ED from a middle-aged man with new chest pain?
-
The FDA has approved a new, but controversial, treatment for Alzheimer’s disease.
-
By shortening the duration of antibiotic therapy, a procalcitonin-guided protocol decreased the rate of infection-associated adverse effects, decreased costs, and reduced mortality in patients with sepsis.
-
The FDA has approved a new treatment for paroxysmal nocturnal hemoglobinuria, a rare, life-threatening blood disease.
